Abstract
Introduction The purpose of VIKING II is to create an observational cohort of volunteers with ancestry from the Northern Isles of Scotland, primarily for identifying genetic variants influencing disease. The new online protocol is separate to, but follows on from, earlier genetic epidemiological clinic-based studies in the isolated populations of Orkney and Shetland. These populations are favourable for the study of rarer genetic variants due to genetic drift, the large number of relatives, and availability of pedigree information.
Methods and Analysis Online methods are being used to recruit ∼4,000 people who have Northern Isles ancestry, living anywhere in the world. The option for participants to have actionable genetic results returned is offered. Broad consent will be taken electronically. Data will be collected at baseline through an online questionnaire and longitudinally through linkage to NHS data in the electronic health record. The questionnaire collects a variety of phenotypes including personal and family health. DNA will be extracted from saliva samples then genome-wide genotyped and exome sequenced. VIKING II aims to capitalise on the special features of the Northern Isles populations to create a research cohort that will facilitate the analysis of genetic variants associated with a broad range of traits and disease endpoints.
Ethics and Dissemination The South East Scotland Research Ethics Committee gave the study a favourable opinion. VIKING II is sponsored by the University of Edinburgh and NHS Lothian. Summary research findings will be disseminated to participants and funding bodies, presented at conferences and reported in peer-reviewed publications.
Article Summary Strengths and limitations of this study
Detailed data and biological sample collection of research volunteers with unique ancestry.
Consent for access to routinely collected clinical EHR data and for future re-contact, providing a longitudinal component.
Optional consent for return of actionable genetic results.
4,000 participants is a relatively small number for certain types of genetic analyses, so the cohort is underpowered on its own, in some study designs.
Resources to maintain the cohort, and to store data and DNA samples, are significant, with sustainability dependent on infrastructure support and continued funding.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://www.researchregistry.com
Funding Statement
This study was funded by the Medical Research Council University Unit award to the MRC Human Genetics Unit, University of Edinburgh, grant number MC_UU_00007/10, Programme MC_PC_U127592696.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The protocol for recruitment and collection of baseline data and saliva samples for the VIKING II cohort has been given a favourable opinion by the South East Scotland Research Ethics Committee, NHS Research Scotland (Ref No: 19/SS/0104).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Shona M. Kerr Shona.kerr{at}ed.ac.uk
Rachel Edwards Rachel.Edwards{at}ed.ac.uk
David Buchanan David.Buchanan{at}ed.ac.uk
John Dean john.dean{at}nhs.scot
Zosia Miedzybrodzka zosia{at}abdn.ac.uk
James F. Wilson jim.wilson{at}ed.ac.uk
Data Availability
All data produced in the present study are available upon reasonable request to the authors
List of abbreviations
- ACMG
- American College of Medical Genetics
- CRF
- Clinical Research Facility
- EHR
- Electronic Health Record
- GCP
- Good Clinical Practice
- GDPR
- The EU General Data Protection Regulation
- LIMS
- Laboratory Information Management System
- MRC
- Medical Research Council (UK)
- NHS
- National Health Service (UK)
- ORCADES
- Orkney Complex Disease Study
- REC
- Research Ethics Committee